Ginkgo to acquire West Sacramento Biologics Research & Development from Bayer for $83m.

Ginkgo, an American biotech company, agreed to acquire West Sacramento Biologics Research & Development from Bayer, a German multinational pharmaceutical and biotechnology company, for $83m. "To ensure sustainable food security for an ever growing population, we need to invest in biological solutions. By acquiring one of the premier R&D sites for agricultural biologicals worldwide and partnering with the best-in-class teams at Bayer and Joyn, we are demonstrating our commitment to developing breakthrough products for growers around the world. We are excited to be able to make this platform accessible to innovative companies and teams who may otherwise not have the resources or expertise to develop these capabilities in house," Jason Kelly, Ginkgo Bioworks CEO and co-founder.